Optimind Pharma Corp. News Releases

Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk

Mon, 08 Sep 2025 15:18:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share exchange agreement dated September 5, 2025 (the "SEA") with IDesk Technologies Private Limited ("InterviewDesk"), a private company incorporated under laws of India, and its principal shareholders in respect of an arm's length transaction (the "Transaction") which will change the business of the...

Optimind Pharma Announces Termination of Letter of Intent

Thu, 04 Sep 2025 16:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated March 18, 2025 with Monjin Interviews Private Limited ("Monjin"), with respect to the Company's acquisition of Monjin, has been mutually terminated by the parties.The Company is continuing to evaluate and review alternative acquisition opportunities.About the CompanyThe Company is a reporting issuer...

Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business

Mon, 24 Mar 2025 23:40:00 -0400

Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March 18, 2025, (the "LOI") to acquire all of the issued and outstanding shares (the "Transaction") of Monjin Interviews Private Limited ("Monjin"), a corporation formed under the laws of India. The Transaction is an arm's length transaction.About Monjin - https://www.monjin.com/Redefining Recruitment...

Optimind Pharma Closes Second Tranche of Private Placement

Mon, 29 Jul 2024 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the second trance of its previously announced private placement. The Company issued 2,500,000 common shares at a price of $0.05 per share to investors for gross proceeds of $125,000. The Company expects to close a third tranche of the private placement in the next couple of weeks.Net proceeds will be used for working capital. All securities issued in...

Optimind Pharma Closes First Tranche of Private Placement

Mon, 08 Jul 2024 16:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") announces it has closed the first trance of its previously announced private placement. The Company issued 2,900,000 common shares at a price of $0.05 per share to investors for gross proceeds of $145,000.The Company expects to close a second tranche of the private placement in the next couple of weeks.Net proceeds will be used for working capital. All securities issued in...

Optimind Pharma - Private Placement

Wed, 03 Jul 2024 16:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces a proposed private placement. The Company intends to issue up to 10,000,000 common shares (the "Shares") at a price of $0.05 per share for gross proceeds of up to $500,000. Net proceeds will be used for working capital. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the...

Optimind Pharma Corp. Announces Grant of Options

Fri, 10 Mar 2023 16:00:00 -0500

Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Optimind Pharma Corp. (CSE: OMND) (the "Company") wishes to announce that pursuant to its stock option plan, it has granted stock options to its directors, officers and consultants on March 8, 2023 to purchase up to 5,900,000 common shares of the Company at an exercise price of $0.05 per common share. The options have a term of four (4) years expiring on March 8, 2027. About Optimind Pharma Optimind Pharma is an emerging provider of...